The global Sjogren’s syndrome market is anticipated to grow at a CAGR of 4.6% during the forecast period (2021-2027). The factors contributing to the growth of the market include rising Sjogren’s syndrome and other autoimmune diseases. For instance, according to the American College of Rheumatology, in a large US observational registry, out of a total of 24,528 patients, 7870 (31.2%) were found to be diagnosed with Sjogren’s syndrome. It was also observed that the syndrome was more likely to be seen in older and female persons and was associated with seropositivity.
(Get 15% Discount on Buying this Report)
Get Report Sample Copy @ https://www.omrglobal.com/request-sample/sjogrens-syndrome-acids-market
Further according to the National stem Cell Foundation, it is estimated by the American Autoimmune related diseases Association (AARDA) that almost 50 million Americans are living with autoimmune diseases bearing a cost of $86 billion per year. As per the US Department of Health and Human Services (HHS), these diseases are the fourth-largest cause of disability among wo9men in the US and the eighth largest cause of women’s mortality rates.
A Full Report of Global Sjogren’s Syndrome Acids Market is Available at: https://www.omrglobal.com/industry-reports/sjogrens-syndrome-acids-market
Moreover, the collaboration between public associations raises awareness regarding the treatment and diagnosis for Sjogren’s syndrome that further projected to propel the market growth during the forecast period. For instance, in May 2018, The American Autoimmune Related Disease Association announce its collaborative partnership with Allegheny Health Network to improve and work towards the health conditions of patients with autoimmune diseases. With this collaboration, both the associations will be on track to accelerate the diagnosis and treatment for curing autoimmune diseases and also fulfil the need and demand for increasing diagnostic and treatment centres.
Global Sjogren’s Syndrome Market Report Segment
By Drug Type
- Pilocarpine
- Cyclosporine
- Hydroxychloroquine
- Immunosuppressive Agents
By Type
- Primary Sjögren’s Syndrome
- Secondary Sjögren’s Syndrome
(This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.)
